Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 08/26 05:31:43 pm
77.4 CHF   +0.13%
12:53a Stada shareholder AOC pushes through board reshuffle
08/26 NOVARTIS AG (NY : NVS) Announces Positive Phase III Results For MS D..
08/25 NOVARTIS' : phase III MS study successfully meets endpoints
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on NOVARTIS AG
07/14 NOVARTIS : Malaria Experts and African Leaders Challenged to Maintain the Moment..
07/14 NOVARTIS : Alcon launches Dailies Total1« Multifocal contact lenses, the first a..
07/13 NOVARTIS : Sandoz biosimilar etanercept recommended by FDA advisory committee fo..
07/13 CAMURUS : announces completion of Phase 2 study of CAM2029 in patients with acro..
07/13 NOVARTIS : Parsippany child day care center gets helping hands
07/13 ASTRAZENECA : Agrees Deal To Resolve Patent Litigation With Sandoz In US
07/13DJASTRAZENECA : Resolves Faslodex Patent Litigation in US
07/13 ASTRAZENECA : AZ resolves Faslodex patent litigation in the US
07/13 NOVARTIS : Les experts du paludisme et les responsables africains mis au défi de..
07/13 NOVARTIS : Malaria experts and African leaders challenged to maintain the moment..
07/13 NOVARTIS : Malaria Experts and African Leaders Challenged to Maintain the Moment..
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12 NOVARTIS : Erin Keaney, at Novartis, to Present at Drug Design & Medicinal Chemi..
07/12 CAMURUS : announces completion of Phase 2 study of CAM2029 in patients with acro..
07/12 NOVARTIS : Search is on for next Int'l BioCamp delegates
07/11 Psoriasis Market with Focus on Plaque Psoriasis Global Industry Analysis with..
07/08 NOVARTIS : Alcon Research Assigned Patent
07/08 NOVARTIS : Elanco offers cost-effective solution for E. coli
07/07 HONDA MOTOR : Patent Issued for Sealed Weld Element for Attachment to a Vehicle ..
07/07 NOVARTIS : Researchers Submit Patent Application, "Crystalline Forms of 5-Chloro..
07/07 XENCOR : Announces Strategic Collaboration for Bispecific Programs, including Xm..
07/07 NOVARTIS : Patent Issued for Systems and Methods for a Membrane-Free Electrolysi..
07/07 NOVARTIS : PKC412 midostaurin pivotal data published in NEJM show 60% response r..
07/07 NOVARTIS : Sandoz announces EGALITY trial results for biosimilar etanercept
07/07 NOVARTIS : New data shows Sandoz biosimilar etanercept candidate has equivalent ..
07/06 NOVARTIS : Edge Therapeutics Announces Appointment of Harry J. Sacks, M.D., FAAP..
07/05 XENCOR : Novartis adds bispecific antibodies to its growing immuno-oncology port..
07/05 NOVARTIS : PKC412 (midostaurin) pivotal data published in NEJM show 60% response..
07/05 NOVARTIS : Largest global psoriasis survey shows 84% of people face discriminati..
07/04 NOVARTIS AG : and Xencor Inc; Geared up to Stamp Out Hematological Ailments
07/03 NOVARTIS INDIA : Quarterly results - novartis india limited
07/03 NOVARTIS INDIA : Trailing twelve month results - novartis india limited
07/01 Future Pricing and Reimbursement Strategies from ABPI, IMS Health, Baxalta, S..
07/01 NOVARTIS : US Respondents to Global Psoriasis Survey Reveal Experiences, Percept..
06/30 INCYTE : FDA Grants Breakthrough Therapy Designation for Incyte's Ruxolitinib Ja..
06/30 NOVARTIS : Timely use of Novartis' Entresto could prevent or postpone over 28,00..
06/30 OPHTHOTECH : Completes Patient Recruitment in Phase 3 Trial of Fovista« Anti-PDG..
06/29 NOVARTIS : PKC412 (midostaurin) pivotal data published in NEJM show 60% response..
06/29 NOVARTIS : Land conservancy gets helping hands
06/29 NOVARTIS : Psoriasis survey reveals discrimination and low treatment expectation..
06/29 NOVARTIS : Largest global psoriasis survey shows 84% of people face discriminati..
06/28 NOVARTIS : and Xencor enter bispecific antibody collaboration
06/28 NOVARTIS : adds bispecific antibodies to its growing immuno-oncology portfolio t..
06/25 NOVARTIS : SC requests solicitor general to consider on biosimilars
06/23 NOVARTIS : Sandoz Canada Concludes a New Collective Agreement With Unionized Emp..
06/23 NOVARTIS : Patent Issued for Sharp Fixation Target (USPTO 9364141)
06/23 NOVARTIS : Field Service Workers Represented by Nichols Kaster, PLLP and JTB Law..
06/22 Roche CEO 'sleeps better' as risk to drugmaker's growth recedes
06/22 NOVARTIS : Timely use of Novartis' Entresto could prevent or postpone over 28,00..
06/22 NOVARTIS : Next-generation antimalarial treatment
06/21 NOVARTIS : "Pure Nebraska" segments filmed at Sandoz Center
06/21 NOVARTIS : CSC professor cycling to Kearney for Sandoz meeting
06/20 Novartis aims to triple biosimilar drugs by 2020
06/20 NOVARTIS : Reigniting the malaria fight
06/18 NOVARTIS : New treatment to tackle cataracts, ophthalmology head says
06/16 NOVARTIS : data show more than 50 percent of eligible Ph+ CML patients maintain ..
06/16 NOVARTIS : Institute for Biomedical Research Details Findings in Chemical Biolog..
06/16 NOVARTIS : Patent Issued for JAK PI3K/MTOR Combination Therapy (USPTO 9358229)
06/16 NOVARTIS : Patent Issued for Method of Treating a Lens Forming Surface of at Lea..
06/16 NOVARTIS : pivotal data for Tafinlar« + Mekinist« demonstrated a 63 percent over..
06/16 NOVARTIS : Expands Partnership with Medicines for Malaria Venture to Develop Nex..
06/15 NOVARTIS : and MMV expand partnership to develop KAF156
06/15 NOVARTIS : étend son partenariat avec Medicines for Malaria Venture pour dévelop..
06/15 NOVARTIS : expands partnership with Medicines for Malaria Venture to develop nex..
06/15 NOVARTIS : expands partnership with Medicines for Malaria Venture to develop nex..
06/13 GOOD PHARMA : How Marketing creates Value in Pharma
06/10 NOVARTIS : Colombia to force Novartis to lower prices of cancer drug
06/10 NOVARTIS : Long-term safety data for Revolade in adults with chronic ITP
06/10 NOVARTIS : highlights long-term safety data of Revolade« in adults with chronic ..
06/10 NOVARTIS : presents data showing Jakavi« is superior to best available therapy i..
06/09 NOVARTIS : Colombia to force Novartis to lower prices of cancer drug
06/09 NOVARTIS : Patent Issued for Biomarkers for IAP Inhibitor Therapy (USPTO 9353419..
06/09 NOVARTIS : Trademark Application for "SEE LOOK FEEL" Filed by Novartis AG
06/09 EISAI : Enters into a Collaboration Agreement to Co-Promote LENVIMA« Lenvatinib ..
06/09 NOVARTIS : announces US collaboration to co-promote Lenvima« in combination with..
Prev.1   2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ($)
Sales 2016 48 839 M
EBIT 2016 11 199 M
Net income 2016 7 849 M
Debt 2016 14 751 M
Yield 2016 3,59%
P/E ratio 2016 23,10
P/E ratio 2017 21,03
EV / Sales 2016 4,61x
EV / Sales 2017 4,48x
Capitalization 210 234 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 89,5 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-9.62%210 234
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-11.47%214 671
PFIZER INC.7.87%211 206
ASTRAZENECA PLC7.33%173 797
MERCK & CO., INC.18.99%173 793
More Results